To assess the prognostic value of the estimation of plasma volume, or of their variation beyond clinical examination in a post-hoc analysis of the Eplerenone Post-Acute Myocardial Infarction (AMI) Heart Failure (HF) Efficacy and Survival Study (EPHESUS).
Introduction
Congestion is the major cause for heart failure (HF) hospitalization. However, many HF patients are discharged with persistent signs and symptoms of congestion, high left ventricular filling pressures 1 and evidence of hypervolemia 2 . Available data suggest that a pre-discharge clinical assessment of congestion is often not performed, and even if performed is not done systematically 1 . The same issue arises after discharge and may contribute to the burden of rehospitalizations. Careful evaluation of all physical findings, laboratory variables, weight change and net fluid change is warranted before discharge, as suggested by guidelines 3 . Among readily available data at discharge biological surrogates of plasma volume and therefore of congestion have been shown to be associated with post-discharge outcomes [4] [5] [6] [7] [8] . Plasma volume may be assessed indirectly using several published methods.
Whether these various methods of plasma volume measurement beyond clinical examination have different prognostic value is unknown and was therefore investigated in this study using data from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Methods

Population
The design and results of the trial have been reported previously 9 . The EPHESUS study enrolled 6632 patients with HF following acute myocardial infarction (AMI) complicated by left ventricular systolic dysfunction (ejection fraction ≤ 40%). HF had to be documented by at least one of the following: presence of pulmonary rales, chest radiography showing pulmonary venous congestion, or the presence of a third heart sound. Clinical signs of pulmonary congestion were not required at inclusion in patients with diabetes mellitus.
Patients were entered into the study from 3 to 14 days post infarction (with inclusion (M0) performed pre-discharge in 80% of patients). All patients were randomly assigned to 6 treatment with eplerenone 25 mg/day or placebo. EPHESUS was an event-driven study with a mean duration of follow-up of 16 months. Clinical assessments were made at inclusion (M0), at month 1 (M1), at month 3 (M3), and every three months thereafter. Among the 6632 patients included in the EPHESUS study, 1675 were excluded from the analysis because of unavailable data at baseline and/or at month 1 (259 died before 5 weeks and 1416 did not have the clinical and/or biological data required for all the analyses conducted in the present study). The present analysis was therefore performed on the 4957 remaining patients.
Study end points
The aim of the present study was to predict early cardiovascular events i.e. cardiovascular death and/or hospitalization for HF (the primary endpoint of the study, adjudicated by a blinded critical event committee, as per trial protocol 9 ) between 1 month and 3 months after AMI with HF (including a sensitivity analysis performed at 6 months in the study population with available hemoglobin and hematocrit data at M0).
Estimation of change in plasma volume
To estimate relative changes in plasma volume (PV) between M0 and M1 three different formulas were tested. The Strauss formula (∆ePVS) uses changes in hemoglobin and hematocrit concentrations and does not provide an instantaneous measure of PV but estimates its change between two time points [10] [11] [12] , while the Kaplan and Hakim formulas respectively estimate instantaneous PV taking into account weight and hematocrit concentration at a given time point 11, 13, 14 . The only formula associated with cardiovascular events in this analysis (see online data supplements: complete statistical section and This formula can be interpreted as the relative change in estimated plasma volume between M0 and M1. For this reason, ePVS was defined as being proportional to this value.
The instantaneous formula for estimating PV, derived from ∆ePVS is:
Variables
Measurements at M0 and M1 included ePVS, NYHA stage, KILLIP class (available at M0 only), weight, estimated glomerular filtration rate (eGFR) assessed by the MDRD formula 15 , blood pressure (BP), hemoglobin and hematocrit concentrations, serum sodium, left ventricular ejection fraction (LVEF) (available at M0 only). ΔePVS and change in the continuous variables between M0 and M1 were also considered together with medical history (age, sex, race, previous hospitalization for HF, reperfusion therapy, previous AMI, diabetes, prior episodes of HF and hypertension). Owing to the number of missing values of albumin and serum protein at M0 and M1 (25%), these variables were not considered in the present analysis. Both were associated with outcomes as well as albumin but not the change in serum protein in univariate analysis (data not shown).
Concise Statistical Analysis section (a complete description is provided as an online data supplement)
All analyses were performed using SAS version 9. In order to select a set of predictors for multivariate analysis, a univariate analysis was performed to test the existence of a significant dependence between each of the initial variables and the two-class variable "event / non-event". A variable was retained if the corresponding p-value was smaller than 0.15 which is commonly used in such approaches.
Moreover, any variable highly correlated with another variable and with a less significant pvalue was not retained.
To examine association with event, a stepwise logistic regression based on the remaining variables was performed by using the likelihood ratio test at a threshold of 0.05. This analysis automatically excluded insufficiently predictive variables. Prognostic gain of ΔePVS or ePVS was assessed by the integrated discrimination improvement (IDI), the continuous net reclassification improvement (NRI) and the increased area under ROC curve (IAUC).
Stepwise discriminant analysis and linear discriminant analysis (LDA) were also performed to verify the stability of the set of retained variables (online data supplements, Table 2 ).
Furthermore, the quality and stability of all models were tested by cross-validation (online data supplements, Table 3 ). Finally, subgroup analyses were performed using a stepwise logistic regression: with and without anemia, anticoagulants, antithrombotic and reperfusion therapy at baseline. Anemia was defined according to the World Health Organization (WHO) criteria as a baseline hemoglobin < 13g/dL for men and < 12 g/dL for women.
Results
Comparison of the characteristics at baseline between included and non-included patients
shows that the 1675 non-included patients generally had more severe HF ( Table 1) .
Baseline, 1-month, and in-between features associated with cardiovascular events in univariate analysis
Patients with events ( Table 2) were older and had a lower LVEF, weight and eGFR at baseline and M1, as well as higher NYHA and KILLIP classes, lower hemoglobin and hematocrit concentrations.
ΔePVS was significantly associated with early cardiovascular (CV) events (p=0.0009). Of note, ePVS at baseline and M1 were also significantly associated with CV events (p<0.0001).
Patients losing weight experienced more frequent events. Of note, ΔePVS and changes in body weight were not significantly correlated (rho=0.02; p=0.093).
Multivariate analysis including ΔePVS
ΔePVS was retained in the logistic regression model (OR=1.01, p=0.004) ( Table 3) Of note, in a sensitivity analysis in the subgroups with and without anemia, ΔePVS was also retained in the models (online data supplements, Table 4 ).
Multivariate analysis including the instantaneous ePVS
ePVS at M1 was retained in the logistic regression model (OR=1.38, p<0.0001) ( Table 4 ).
The three measures of added predictive ability of ePVS at M1 were positive and significant: relative IDI = 15.06 % (p=0.004), NRI=0.18 (p=0.004), IAUC=0.01 (p=0.035).
With regard to sensitivity analyses: i) ePVS M1 was a better predictor of early cardiovascular events than ΔePVS (online data supplements). ii) In the subgroups with and without anemia at baseline, ePVS M1 was retained in the models as was the case in the subgroups with and without anticoagulants, antithrombotics and reperfusion therapy at baseline (online data 10 supplements, Table 4 ). iii) In a larger EPHESUS dataset (i.e. which included 5845 or 5880 patients with available hemoglobin or hematocrit measurements at M0), ePVS M0 was only marginally associated with event occurrence at M1 (p=0.051), whereas it was significantly associated with 90-day events (OR=1.12, p=0.007; NRI: p=0.027; IDI: p=0.075) and 180-day events (OR=1.14, p=0.0006; NRI: p=0.0003; IDI: p=0.002). Of note, when ePVS M1 was considered in lieu of ePVS M0, it was retained in the model (p<0.0001) and significantly increased the predictive capacity of the model (data not shown). iv) In a subset of the EPHESUS population with available Brain Natriuretic Peptide (BNP) measurements, we previously reported significant positive correlations between changes in BNP and plasma volume, as assessed by the Strauss Formula between baseline and month 1 5 . Present analysis of this subset of 346 patients showed that BNP and instantaneous ePVS at M0 and M1 were significantly but weakly correlated (rho=0.23, p<0.0001 at M0, and 0.25, p<0.0001 at M1).
Among this subset, 14 patients experienced a CV event. BNP M1 (AUC=0.88) and ePVS M1 (AUC=0.78) were good predictors of CV events in univariate analysis although the model had an even greater discriminative ability when both variables were combined (AUC=0.90) ( Figure 1) . With regard to the added predictive ability of ePVS M1 in the model including both variables, the three measures were positive and only IAUC was not significant: relative IDI=129.9% (p=0.029), NRI=0.89 (p=0.0006), IAUC=0.02 (p=0.36). However, owing to the small number of CV events, these last results should be interpreted with caution,
Discussion
To our knowledge, the results of this analysis show for the first time that in patients with HF and left ventricular systolic dysfunction complicating AMI a short-term (one month) decrease in estimated plasma volume using the Strauss formula (i.e. decongestion) was associated with better cardiovascular outcomes independent from the clinical variables used in routine practice (e.g. NYHA, KILLIP class, body weight, BP, LVEF, eGFR). Moreover, we found that an instantaneous estimation of plasma volume directly derived from the Strauss formula displayed greater prognostic value. An instantaneous plasma volume estimation should enable physicians to immediately and reliably assess the patient's congestive status beyond usual routine clinical assessment and natriuretic peptide measurement.
The non-invasive assessment of plasma volume is important in the management of HF patients to tailor diuretic doses to the needs of the individual patient, as recommended by all current guidelines 3, 16 but often not achieved due to the unreliability of clinical signs and symptoms. In the present study a majority of patients received loop diuretics at baseline, with these patients experiencing more events. Of note, observational studies have shown an association between high-dose loop diuretics and adverse outcomes. However, these studies are confounded by the fact that patients receiving higher doses of diuretics tend to have greater disease severity and/or comorbidity 17 . In the present series decongestion between baseline and at one-month, as assessed by a decrease in estimated plasma volume, was found to be associated with better clinical outcomes. This finding corroborates and extends data derived from 3 randomized trials in acute decompensated HF reporting an association between decongestion (as assessed by biological surrogates of plasma volume) during index hospitalization and better outcomes. An analysis of the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) trial investigated baseline-to-discharge increases in hematocrit, albumin and total protein values.
Patients with values ≥ 2 among the three aforementioned variables in the top tertile were considered to have evidence of hemoconcentration, which was associated with greater net weight/fluid loss and greater reductions in right atrial pressure and pulmonary capillary wedge pressure, along with a substantially lower risk of mortality 4 . In an analysis of the PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function) study, hemoconcentration was defined as an increase in hemoglobin levels between baseline and day 7 in patients presenting with acute decompensated HF. A rapid increase in hemoglobin during hospitalization was related to improved 180-day survival 6 . In the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial, analysis of the absolute in-hospital hematocrit changes calculated between baseline and discharge or day 7 (whichever occurred first) showed that patients with hemoconcentration (i.e. ≥ 3% absolute increase in hematocrit) were less likely to have clinical congestion at discharge, while every 5% increase in in-hospital hematocrit change was associated with decreased cardiovascular mortality or HF hospitalization at ≤ 100 days post randomization 7 .
The present study, the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), provided an opportunity to monitor decongestion whilst using both clinical and biological variables after discharge, between baseline and one month, a critical time frame in terms of rehospitalization burden. Several formulas were used to estimate instantaneous plasma volume and respective changes between baseline and onemonth post-myocardial infarction in patients with HF. In a head-to-head comparison during univariate analysis, only the Strauss formula (to assess variations) and its instantaneous derivation were associated with 3-month outcomes. This formula contains hemoglobin ratios and therefore includes both hemoglobin changes, which may be relevant in HF patients with the cardiorenal anemia syndrome 18 , and multifactorial changes involving medications as well as bone marrow dysfunction associated with kidney dysfunction, inflammation and malnutrition. Although both hematocrit and hemoglobin and their respective changes were also associated with outcomes under univariate analysis, they were not considered in the multivariate analysis, owing to the collinearity with plasma volume estimation and to the uncertainty related to the relative contribution of congestion and anemia in these variables. 13 Hemoconcentration, as evidenced by a rising hematocrit, is an appropriate surrogate indicating that the plasma refill rate has been exceeded by the rate of fluid removal, which can be easily and continuously measured by using an in-line hematocrit sensor during ultrafiltration therapy 19 . Importantly, however, in the subgroups with and without anemia at baseline, ΔePVS or ePVS at M1 were always retained in the multivariate models. The fact that both the Kaplan and Hakim formulas were not associated with outcomes may arise from the integration of body weight in both formulas. Indeed, both Kaplan and Hakim ePV increase when hematocrit decreases and conversely decrease when weight decreases, while patients with events displayed lower weight and hemoglobin. Ideally, dry weights (i.e. the body weight measured in non-congested patients), not assessed in the present study and difficult to estimate in routine practice owing to frequently persisting edema in HF patients, should have been used to run these two formulas. Moreover, body weight loss, which was found to be associated with worse outcomes, may rather be associated with cachexia [20] [21] [22] , as opposed to decongestion, and therefore may be misleading for monitoring congestive status.
Several limitations should be acknowledged in the present study. First, the analysis in the EPHESUS patient population was performed in myocardial infarction patients with HF and altered ejection fraction and, thus, the external validity of these results remains to be assessed in other patient populations. In any event, the present results are hypotheses-generating stemming from a post-hoc analysis and should be confirmed by further prospective investigations. Of importance, we believe that the statistical results are robust, considering that two different methods of discrimination (LR and LDA) were used to create an event prediction model in order to verify the consistency of the results. Finally, the stability of the models was tested by performing cross-validations with ΔePVS or ePVS being consistently selected in the models. 14 
Secondly
, changes in plasma volume, as estimated by the Strauss formula, were assessed by a proposed 10 indirect estimation of plasma volume changes. This is a validated (upon comparison with a radiolabeled gold standard) method integrating hematocrit changes which is routinely used to estimate plasma volume in patients with scheduled plasma exchanges 23, 24 , or even ultrafiltration in the HF setting 25 , whereas notably no specific validation has been reported to date in the HF setting. Interestingly, a sensitivity analysis showed that BNP (as a surrogate of cardiac congestion) measured in 346 patients and instantaneous ePVS were significantly but weakly correlated, and that the coexistence of both elevated BNP and elevated instantaneous ePVS at month 1 was more prone to predict worse outcomes than either alone, which further strengthens the pathophysiological relevance of plasma volume estimation beyond the usual tools.
In conclusion, in the setting of HF complicating AMI, our data provide important insights related to congestion assessment and its post discharge prognostic value, using a simple estimation of plasma volume (with the Strauss formula or its instantaneous derivate) beyond usual clinical variables which may therefore have major clinical implications for patient management. We suggest that monitoring plasma changes in volume may be useful to guide therapy optimization in patients after discharge from a HF hospitalization which remains an important unmet need. Dedicated prospective outcome studies evaluating the role of the Strauss formula to estimate changes in plasma volume are warranted.
Clinical perspectives
Competency in Medical Knowledge: the use of a simple tool to estimate plasma volume may enable to better detect congestion in heart failure patients Caption: ROC curves from univariate and multivariate logistic regression in the subset of the study population (n= 346, 14 with CV events) with available BNP and ePVS measurements at M1. The events considered between month 1 and month 3 after acute myocardial infarction were cardiovascular death and/or hospitalization for heart failure. Values are expressed as medians [inter-quartile range] or proportions where appropriate.
Tables
M0: baseline measurement, M1: measurement at month 1, ∆ePVS: plasma volume variation estimated by Strauss formula. See legends of Tables 1 for remaining abbreviations. * Absolute change between month one and baseline. # Relative change between month one and baseline. 
Three formulas of change in plasma volume
To estimate relative changes in PV between M0 and M1, three different formulas were used. 
Selection of variables for modeling.
In order to select the set of predictors for multivariate analysis, an univariate analysis was performed to test the existence of a significant dependence between each of the initial variables and the two-class variable "event / non-event". A variable was retained if the corresponding p-value was smaller than 0.15. Moreover, any variable highly correlated with another variable and with a less significant p-value was not retained.
Among the three formulas describing changes in PV, only the Strauss formula was retained as potential explanatory variable for entry into the models given that it was highly correlated with the two other formulas (rho=0.82 with Kaplan, rho=0.87 with Hakim) and was the most significant.
The variations in individual hemoglobin and hematocrit values were not retained because of the expected correlations with ∆ePVS (rho=-0.97 for hemoglobin variation, rho=-0.94 for hematocrit variation). The same applies for the hemoglobin and hematocrit levels at baseline and M1 which are involved in the calculation of ePVS (at M1, rho=-0.97 with hemoglobin, rho=-0.93 with hematocrit).
With regard to weight variables, weight at M0 was not retained firstly because of its strong correlation with weight at M1 (rho=0.98) and secondly because it was less significant. For the same reasons, eGFR M0 was not retained (rho=0.70), whereas eGFR at M1 was selected.
Modelisation
The selected variables were used in two discrimination methods. Since in supervised learning, keeping non discriminant predictors can increase the misclassification error, stepwise logistic regression (which simultaneously performs variable selection and classification) was first used, after which a stepwise discriminant analysis and a linear discriminant analysis (LDA) were used in order to perform variable selection and classification, respectively.
At the end of the stepwise logistic regression, from which a set of variables is retained, the probability of belonging to the "event" class for each patient can be estimated from the obtained model. If this probability is greater than a given threshold, then the patient is classified into the "event" class. is greater than an optimal threshold, then this patient is classified into the "event" class. The threshold is determined in the same manner as explained previously.
Model validation
Quality checks and stability of classification rules were tested. Sensitivity and specificity were calculated for each method in resubstitution, that is by using the sample of patients from which the classification rule is defined. Given that this particular measure of the quality of a classification rule is generally too optimistic since it is tested on patients who served to build it., a cross-validation was therefore undertaken in order to gain a more accurate measure of quality. In this resampling method, the sample was divided into m classes of patients. One of the m classes being fixed, a classification rule was then established from the other (m-1)
classes and applied to the individuals of the fixed class. This is repeated m times by changing at every time the fixed class such that each individual in the sample is classified using a rule to the construction of which the individual did not participate. The sensitivity, specificity and value of criterion are thus calculated which more accurately represent the quality of the rule.
A too great difference between these calculated values and those obtained by resubstitution ultimately points to an instability of the model, which in this case is not retained.
Sensitivity analysis
Patients in the non-event sample were drawn at random 1000 times, similar to that found in the event sample. By performing stepwise logistic regression on these samples, ePVS M1 was selected 978 times and Δ ePVS 423 times. Thus it appears that ePVS M1 is a better predictor of early cardiovascular events than Δ ePVS. M0: baseline measurement. M1: measurement at month 1. ePV: estimated plasma volume, ∆ ePV: estimated relative change in plasma volume between month one and baseline. 
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